Open Access

The role of phosphoinositide 3-kinase subunits in chronic thyroiditis

  • Katarzyna Wojciechowska-Durczynska1,
  • Kinga Krawczyk-Rusiecka1,
  • Anna Cyniak-Magierska1,
  • Arkadiusz Zygmunt1,
  • Stanisław Sporny2 and
  • Andrzej Lewinski1Email author
Thyroid Research20125:22

https://doi.org/10.1186/1756-6614-5-22

Received: 10 November 2012

Accepted: 11 December 2012

Published: 21 December 2012

Abstract

Background

The risk of neoplastic transformation in patients with chronic thyroiditis (Hashimoto’s thyroiditis – HT) is slightly increased. Genetic background of this observation is still unclear. PI3K isoforms are linked with inflammatory and neoplastic processes, thus they appear to be interesting subjects of a research in this respect. The aim of our study was to assess the PIK3CA, PIK3CB, PIK3CD and PIK3CG genes expression levels in HT.

Methods

Following conventional cytological examination, 67 thyroid FNAB specimens, received from patients with HT, were quantitatively evaluated regarding PIK3CA, PIK3CB, PIK3CD and PIK3CG expression levels by real-time PCR in the ABI PRISM ®7500 Sequence Detection System.

Results

The performed analysis has revealed significantly higher expression levels (RQ) of PIK3CD, PIK3CG and PIK3CA genes in comparison with PIK3CB gene (p<0.05) and significantly higher gene expression level of PIK3CD in comparison with PIK3CA (p<0.05).

Conclusion

The observed increased PIK3CD, PIK3CG genes expression in HT is probably related to lymphocyte infiltration commonly seen in this condition, however, the role of increased PIK3CA gene expression in the multi-step carcinogenesis process cannot be excluded.

Keywords

Chronic thyroiditis PI3K isoforms

Background

Inflammatory processes protect the body against infection and injury, however, if not satisfactorily regulated, it can lead to destructive consequences, including the development of autoimmune diseases. The inflammation has also been proved to play an important role in other diseases which have not previously been considered to possess inflammatory etiology, e.g. such as cancer. Likewise, a number of researchers reported on an association between chronic thyroiditis (Hashimoto’s thyroiditis – HT) and a risk of thyroid neoplastic transformation.

The PI3K (phosphoinositide 3-kinase) signaling pathway regulates numerous cell functions in both normal and pathological states. Class I PI3K consists of four isofoms of the catalytic subunits, p110α, -β, -δ, -γ, coded by PIK3CA, -B, -D and –G genes, respectively. Under basal conditions, the expression of the PI3K isoforms seems to depend on transcriptional control, with mRNA levels correlating well with protein levels [1]. Moreover, it is well documented that these isoforms show different tissue distribution, i.e. PIK3CA and PIK3CB are expressed ubiquitously, while PIK3CD, PIK3CG are expressed predominantly in leucocytes [2].

Considering thyroid neoplasms, the increased activation of PI3K pathway could be related to mutations and/or amplification of PIK3CA gene and amplification of PIK3CB gene [3]. Additionally, several reports demonstrate that PIK3CD and PIK3CG subunits are essential in regulating chemokine production by leukocytes, as well as directional migration of these cells during the inflammatory process [2, 3]. Thus, a role of PI3K isoforms in the thyroid immune response linked with inflammation and cancer appears to be an interesting subject of a research.

The aim of our study was to assess the PIK3CA, PIK3CB, PIK3CD and PIK3CG genes expression levels in HT.

Material and methods

The study was approved by the Ethics Committee of the Medical University of Lodz, Poland. Written consent was obtained from all the patients subjected to the fine needle aspiration biopsy (FNAB).

Cytological specimens from 67 patients (64 women, 3 men) with chronic thyroiditis were analyzed. Following preparation of smears for cytological examination, extraction of total RNA from remnant biopsy needle material was obtained by an RNeasy Micro Kit (Qiagen), using modified Chomczynski and Sacchi’s method. The purity of total RNA was assessed by NanoDrop® ND-100 spectrophotometr. One hundred nanogram of total RNA was used in the first strand cDNA synthesis with TaqMan® Reverse Transcription Reagents (Applied Biosystems), according to manufacturers’ instruction.

Real-time PCR was performed on the ABI PRISM® 7500 Sequence Detection System (Applied Biosystems) by using Taq Man® Universal PCR Master Mix (Applied Biosystems) and Taq Man® Gene Expression Assays probe and primer mix (Applied Biosystems) according to the manufacturers’ specification. The Assay Identification numbers were: PIK3CA - Hs00180679_m1; PIK3CB - Hs00178872_m1; PIK3CD - Hs00192399_m1; PIK3CG - Hs00176916_m1. Thermal cycler conditions were as follows: hold for 10 min. at 95°C, followed by two-step PCR for 50 cycles of 95°C for 15 s and followed by 60°C for 1 min. Amplification reactions were performed in triplicate for each sample, and the results were normalized to the ACTB gene expression level (ACTB Assay Identification number: Hs99999903_m1). Macroscopically unchanged thyroid tissue, surgically removed from patients with nodular goitre, served as a control for real-time PCR experiment.

An analysis of relative gene expression data was performed, using the 2-ΔΔCT method on an ABI PRISM® 7500 Sequence Detection System Software (Applied Biosystems). The fold change in studied gene expression, normalised to endogenous control, was calculated using formula: RQ = 2-ΔΔCT.

In order to compare the relative expression (RQ) of PIK3CA, PIK3CB, PIK3CD and PIK3CG genes in HT, the data were statistically analysed using Kruskal-Wallis’ and Newman-Keuls’ tests. In all analyses, statistical significance was considered achieved at a value of p<0.05.

Results

The performed analysis has revealed significantly higher expression levels (RQ) of PIK3CD, PIK3CG and PIK3CA genes in comparison with PIK3CB gene (p<0.05). Further statistical analysis proved significantly higher gene expression level of PIK3CD in comparison with PIK3CA (p<0.05) (Figure 1, 2).
Figure 1

Box-and-whisker plots representing the expression of PIK3CA , PIK3CB , PIK3CD and PIK3CG genes in HT. The results are calculated as RQ values. Whiskers represent standard deviation for particular genes. Boxes represent standard error of mean. Small boxes illustrate means. The results were statistically analyzed, using Kruskal-Wallis’ and Newman-Keuls’ tests (p<0.05).

Figure 2

Box-and-whisker plots representing the expression of PIK3CA , PIK3CB , PIK3CD and PIK3CG genes in HT. The results are calculated as RQ values. Whiskers represent minimum and maximum value for particular genes. Boxes represent lower quartile and upper quartile of values. Small boxes illustrate median values. The results were statistically analyzed, using Kruskal-Wallis’ and Newman-Keuls’ tests (p<0.05).

Discussion

Chronic thyroiditis affects a significant portion of endocrinologic patients, with considerable quality-of-life burden. When discussing chronic thyroiditis, it is worth stressing that former studies revealed infiltration of thyroid tissue by a mixed population of T and B lymphocytes [4]. Moreover, chronic thyroiditis is characterized by the presence of thyroid antibodies; antibodies against thyroperoxidase (TPO) are the most specific ones.

PI3K isoforms control inflammation processes at many levels, from the generation of inflammatory cells to their migration and function. However, the precise role of PI3K in the regulation of immune process in the thyroid remains open to refinement. Genetic approaches have been employed to assess the contribution of class I PI3K isoforms in thyroid immune process. Our present findings have confirmed increased expression of PIK3CA, PIK3CD and PIK3CG genes and decreased expression of PIK3CB gene in HT. Further statistical analysis has revealed the increased expression level of PIK3CD in comparison with PIK3CA.

Our results are partially in agreement with previous observations that PIK3CD subunit is expressed at high levels in lymphocytes and lymphoid tissue and may – therefore - play a role in PI3K mediated signaling in the immune system [5]. In addition, PIK3CD has been implicated in leukocyte endothelial transmigration during inflammation [6] but it is not clear whether this effect is caused by PIK3CD expression in leukocytes themselves, in endothelial cells or by both.

The role of PIK3CD isoform in thyroid carcinogenesis remains to be determined, however it is worth stressing that PIK3CD contributes in other neoplastic processes. In acute myeloid leukemia cells, PIK3CD is the only class I PI3K isoform that consistently is detected [7, 8]. At the same time, PIK3CD is expressed to moderate degree in certain neoplastic cells of non-leukocyte origin, such as melanoma cells, breast and colon cancer cells. However, large discrepancies in expression levels in cell lines, even of the same tissue origin, were noted [9].

The explanation of our findings can also be related to the process of antibodies generation which requires collaboration between B and T cells within germinal centers, the process in which PIK3CD subunit is essential in T cells just for the germinal centre reaction. Additionally, it has also been found that formation of T follicular helper cells is critically dependent on PIK3CD [10].

Furthermore, the contribution of PIK3CD subunit in other autoimmune disorders, like rheumatoid arthritis has also been confirmed and PIK3CD is a promising therapeutic target in this disease because of its role to leukocyte biology [11]. It has also been demonstrated that PIK3CD is a major regulator of PDGF-mediated fibroblast growth [11], the observation which can support the role of PIK3CD also in the process of thyroid fibrosis in HT.

In our present investigation we have demonstrated high expression of PIK3CG gene in HT. It has previously been regarded that PIK3CG subunit is required to allow chemotactic migration of neutrophils, macrophages, and effector CD8 T cells to inflammatory sites [12, 13]. The increased PIK3CG gene copy number has been documented in ovarian cancer, as well [14].

Previous findings by Ghigo et al. [15], together with our present observations, suggest that PIK3CD and PIKCG can be involved in inflammation processes and can influence the immune system. Both PIK3CD and PIK3CG had also been identified as validated drug targets in immune and inflammatory diseases [16]. Nevertheless, the non-redundant but related roles of PIK3CD and PIK3CG have made it difficult to determine which of the two isoforms (alone or in combination) is best targeted in a particular inflammatory disorder.

However, it should be recalled that the increased expression of p110 isoform, especially of isoform of p110α, induced also oncogenic transformation [3]. Amplification and mutations in PIK3CA gene have been reported in many human cancers, including thyroid cancer, especially in follicular thyroid carcinoma and undifferentiated thyroid carcinoma [3]. Still, little is known about the precise role of PIK3CA gene in inflammatory disorders in thyroid gland, however, the increased expression in Riedel’s thyroiditis has previously been observed in our laboratory [17].

In conclusion, the present study speaks for contribution of PIK3CD, PIK3CG and PIK3CA isoforms to the autoimmune processes in the thyroid. The observed increased PIK3CD, PIK3CG genes expression in HT is probably related to infiltration of lymphocytes, however, the role of the increased PIK3CA gene expression in the multi-step carcinogenesis process cannot be excluded, either.

Declarations

Acknowledgments

This study was supported by the funds from the Medical University of Lodz, Poland (No. 503/1-107-03/503-01 and project No. 502-03/1-107-03/502-14-086).

Authors’ Affiliations

(1)
Department of Endocrinology and Metabolic Disease, Medical University of Lodz, Polish Mother’s Memorial Hospital – Research Institute
(2)
Department of Dental Pathology, Medical University of Lodz, The Clinical-Didactic Centre

References

  1. Geering B, Cutillas PR, Nock G, Gharbi SI, Vanhaesebroeck B: Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc Natl Acad Sci U S A 2007, 19: 7809–7814.View ArticleGoogle Scholar
  2. Nakamura H, Dan S, Akashi T, Unno M, Yamori T: Absolute quantification of four isoforms of the class I phosphoinositide-3-kinase catalytic subunit by real-time RT-PCR. Biol Pharm Bull 2007, 6: 1181–1184.View ArticleGoogle Scholar
  3. Xing M: Genetic alterations in the phosphatidylinositol-3 kinase/akt pathway in thyroid cancer. Thyroid 2010, 7: 697–706.View ArticleGoogle Scholar
  4. Biddinger PW: Thyroiditis. In Diagnostic Pathology and Molecular Genetics of the Thyroid: A Comprehensive Guide for Practicing Thyroid Pathology. Edited by: Nikiforov YE, Biddinger PW, Thompson LDR. Lippincott Williams&Wilkins; 2009:39–59.Google Scholar
  5. Chantry D, Vojtek A, Kashishian A, Holtzman DA, Wood C, Gray PW, Cooper JA, Hoekstra MF: p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem 1997, 31: 19236–19241.View ArticleGoogle Scholar
  6. Puri KD, Doggett TA, Huang CY, Douangpanya J, Hayflick JS, Turner M, Penninger J, Diacovo TG: The role of endothelial PI3Kgamma activity in neutrophil trafficking. Blood 2005, 1: 150–157.View ArticleGoogle Scholar
  7. Billottet C, Grandage VL, Gale RE, Quattropani A, Rommel C, Vanhaesebroeck B, Khwaja A: A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 2006, 50: 6648–6659.View ArticleGoogle Scholar
  8. Sujobert P, Bardet V, Cornillet-Lefebvre P, Hayflick JS, Prie N, Verdier F, Vanhaesebroeck B, Muller O, Pesce F, Ifrah N, Hunault-Berger M, Berthou C, Villemagne B, Jourdan E, Audhuy B, Solary E, Witz B, Harousseau JL, Himberlin C, Lamy T, Lioure B, Cahn JY, Dreyfus F, Mayeux P, Lacombe C, Bouscary D: Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 2005, 3: 1063–1066.View ArticleGoogle Scholar
  9. Sawyer C, Sturge J, Bennett DC, O’Hare MJ, Allen WE, Bain J, Jones GE, Vanhaesebroeck B: Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta. Cancer Res 2003, 7: 1667–1675.Google Scholar
  10. Rolf J, Bell SE, Kovesdi D, Janas ML, Soond DR, Webb LM, Santinelli S, Saunders T, Hebeis B, Killeen N, Okkenhaug K, Turner M: Phosphoinositide 3-kinase activity in T cells regulates the magnitude of the germinal center reaction. J Immunol 2010, 7: 4042–4052.View ArticleGoogle Scholar
  11. Bartok B, Boyle DL, Liu Y, Ren P, Ball ST, Bugbee WD, Rommel C, Firestein GS: PI3 kinase δ is a key regulator of synoviocyte function in rheumatoid arthritis. Am J Pathol 2012, 5: 1906–1916.View ArticleGoogle Scholar
  12. Sasaki T, Irie-Sasaki J, Jones RG, Oliveira-dos-Santos AJ, Stanford WL, Bolon B, Wakeham A, Itie A, Bouchard D, Kozieradzki I, Joza N, Mak TW, Ohashi PS, Suzuki A, Penninger JM: Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration. Science 2000, 5455: 1040–1046.View ArticleGoogle Scholar
  13. Martin AL, Schwartz MD, Jameson SC, Shimizu Y: Selective regulation of CD8 effector T cell migration by the p110γ isoform of phosphatidylinositol 3-kinase. J Immunol 2008, 4: 2081–2088.View ArticleGoogle Scholar
  14. Zhang L, Huang J, Yang N, Greshock J, Liang S, Hasegawa K, Giannakakis A, Poulos N, O’Brien-Jenkins A, Katsaros D, Butzow R, Weber BL, Coukos G: Integrative genomic analysis of phosphatidylinositol 3’-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin Cancer Res 2007, 18: 5314–5321.View ArticleGoogle Scholar
  15. Ghigo A, Damilano F, Braccini L, Hirsch E: PI3K Inhibition in inflammation: toward tailored therapies for specific diseases. Bioessays 2010, 3: 185–196.View ArticleGoogle Scholar
  16. Rommel C, Camps M, Ji H: PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol 2007, 3: 191–201.View ArticleGoogle Scholar
  17. Wojciechowska-Durczyńska K, Durczyński A, Sporny S, Strzelczyk J, Lewiński A: Riedel’s thyroiditis - a case report with genes’ expression studies. Thyroid Res 2012, 1: 2.View ArticleGoogle Scholar

Copyright

© Wojciechowska-Durczynska et al.; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement